Correction to “Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl‐tRNA synthetase inhibitor, in healthy subjects”

Documents similaires

• No drug–drug interactions between selective prolyl‐tRNA synthetase inhibitor, bersiporocin, and pirfenidone or nintedanib in healthy participants
  par: Wonsuk Shin, et autres
  Publié: (2024)
• Safety, pharmacokinetics, and pharmacodynamics of sofnobrutinib, a novel non‐covalent BTK inhibitor, in healthy subjects: First‐in‐human phase I study
  par: Kyoko Miyamoto, et autres
  Publié: (2024)
• Safety, pharmacokinetics, and pharmacodynamics of ART‐648, a PDE4 inhibitor in healthy subjects: A randomized, placebo‐controlled phase I study
  par: Akira Tanaka, et autres
  Publié: (2024)
• Safety, pharmacokinetics, and pharmacodynamics of anti‐IL‐4Rα antibody SHR‐1819 in healthy subjects: A randomized, controlled phase I study
  par: Na Li, et autres
  Publié: (2024)
• Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor ESK‐001 using a randomized, double‐blind, placebo‐controlled study design
  par: Sibel Ucpinar, et autres
  Publié: (2024)